AANextra AN OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF NEUROLOGY
Sunday, April 3, 2022
PRESIDENTIAL PLENARY SESSION RECOGNIZES NEUROLOGY GIANTS An impressive lineup will address attendees for the premier lectures at this morning’s Presidential Plenary Session from 9:15 a.m. to 12:00 p.m. in Hall 4A. The hugely popular session will be moderated by Science Committee Chair Natalia S. Rost, MD, MPH, FAAN, FAHA, and open to all meeting attendees. Neuroscience Research Prize recipients will also be recognized during the session.
Presidential Lecture
Post-COVID Challenges to Scientific Research
“The Presidential Plenary is the ultimate platform for recognizing some of the biggest names and greatest accomplishments in neurology,” said Rost. “This year’s Presidential Plenary will also shed light on the key issues of our times— the COVID-19 pandemic challenges to scientific research and health equity. This is one session you won’t want to miss!” What is your aha moment from the Presidential Plenary Session? Join the conversation at #AANAM.
Brenda Banwell, MD, FAAN Philadelphia, PA
Merit E. Cudkowicz, MD, MSc Boston, MA
Nina F. Schor, MD, PhD, FAAN Bethesda, MD
Opening Luncheon Kicks off Four Days of Exhibit Hall Happenings Head over to the Exhibit Hall on Level 4 today beginning at 11:30 a.m. for the always popular Opening Luncheon, sponsored by ANI Pharmaceuticals, Inc. (booth 139), that kicks off four days of happenings you won’t want to miss! There will be enhancements to the regular lunch in the Exhibit Hall including hearty soup and root beer float bar. Continued on page 4 u
Autism and Genetics
Daniel H. Geschwind, MD, PhD Los Angeles, CA
Sidney Carter Award in Child Neurology
Vascular Pediatrics Catherine M. AmlieLefond, MD, FAAN Seattle, WA
Robert Wartenberg Lecture
Leaving No One Behind: Charting the Course to Cerebrovascular Health Equity Bruce I. Ovbiagele, MD, MSc, FAAN San Francisco, CA
Live Fireside Chat to Follow Presidential Plenary Session Head over to the Research Connections Learner Engagement Center in Hall 4C-4 from 12:15 p.m.–12:45 p.m. to engage with and ask questions of plenary moderators and presenters during the live, 30-minute fireside chat!
George C. Cotzias Lecture
INSIDE
8
Medical Students Connect with the Pros for Valuable Insights
10
Get Ready to Reunite at Tonight’s Great Neuro Reunion Party!
27
APPs, Make the Most of Your Annual Meeting Experience!
The Vision of the AAN is to be indispensable to our members.
Issue Highlights
6
021 Successes Touted 2 at AAN Business Meeting
Contact Information:
The annual Business Meeting of the American Academy of Neurology was held yesterday, and the 2021 activities and finances were highlighted by President Orly Avitzur, MD, MBA, FAAN; CEO Mary E. Post, MBA, CAE; and Treasurer Charles C. Flippen II, MD, FAAN.
7
New Brain & Life Podcast Debuts
8
oday’s Invited Science T Examines Epilepsy
9
The Mission of the AAN is to promote the highest quality patient-centered neurologic care and enhance member career satisfaction.
The AAN’s new Brain & Life podcast is an entertaining weekly podcast exploring the intersection of brain health and neurologic disease.
Today’s Invited Science Session from 1:00 p.m. to 3:00 p.m. on epilepsy will feature authors giving encore presentations of top abstracts presented at subspecialty meetings.
pplications Open for Three Transformative A Leadership Development Opportunities Applications are now open for three premier AAN Leadership Development Programs: Diversity Leadership, Emerging Leaders, and Practice Leadership.
13
The Role of Industry at the AAN Annual Meeting
16
Congratulate These AAN Service Awards Recipients
As we come back together for the Great Neuro Reunion to focus on the latest in neurology and improved patient care, there are three primary reasons the meeting would not be a complete reunion without the presence of industry.
Take a moment to offer your congratulations to these neurology professionals who are being honored for their service during the Annual Meeting.
Correction In an article on Case Studies programming in the Saturday issue of AANextra, a photo of Vivian Lee, MD, was used instead of a photo of Vivien H. Lee, MD, FAAN. The AAN apologizes for the error. Vivien H. Lee, MD, FAAN
2
2022 Annual Meeting • AANextra
American Academy of Neurology 201 Chicago Avenue Minneapolis, MN 55415 USA Phone: (800) 879-1960 (Toll Free) or (612) 928-6000 (International) Fax: (612) 454-2744 Email: memberservices@aan.com Website: AAN.com AAN Chief Executive Officer: Mary E. Post, MBA, CAE Managing Editor: Angela M. Babb, MS, CAE, APR Editor: Tim Streeter Writers: Ryan Knoke, Sarah Parsons Designer: Andrew Imholte Photography: Will Evans Email: aannews@aan.com AANextra is published by the American Academy of Neurology. The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world. “American Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.
Rost Covers Top Science with Media in Press Conference
Natalia S. Rost, MD, MPH, FAHA, FAAN
Nancy J. Newman, MD, FAAN
Douglas J. Weber, PhD
Joanna Hellmuth, MD, MHS
Natalia S. Rost, MD, MPH, FAHA, FAAN, chair of the Science Committee, spoke to reporters during a press conference on exciting research from researchers Nancy J. Newman, MD, FAAN, of Emory University School of Medicine in Atlanta; Douglas J. Weber, PhD, of Carnegie Mellon University in Pittsburgh; and Joanna Hellmuth, MD, MHS, of the University of California, San Francisco. Newman’s abstract is titled "The Phase III REFLECT Trial: Efficacy and Safety of Bilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)." Weber presented on "Long-Term Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis: Results of SWITCH, a First-in-Human Study." Hellmuth’s abstract is "Cognitive Symptoms After Mild SARSCoV-2 Infection Associate with Higher Levels of CSF Immune Activation and Immunovascular Markers." A recording of the press conference, which was held on March 29 via video conference, is available on the AAN YouTube channel at youtube.com/AANChannel. 0 HSCI-P000627 IDO AAN Congress (new) half-page ad CMYK 06 PRINTREADY.pdf
1
17/03/2022
10:30
Industry Therapeutic Update from Idorsia Pharmaceuticals A Panel Discussion on the Nights and Days of Insomnia
Come see us at Booth 1805 for exciting information about sleep
On behalf of Idorsia Pharmaceuticals, we are pleased to invite you to a dinner program on insomnia with the following faculty:
Alon Y. Avidan, MD, MPH, FAAN, FAASM
Paul Doghramji, MD, FAAFP
Director, UCLA Sleep Disorders Center Professor, UCLA Department of Neurology Los Angeles, CA
Senior Family Physician Collegeville Family Practice Collegeville, PA
Ashgan Elshinawy, DO
Rachel Marie E. Salas, MD, Med, FAAN
Pulmonary and Sleep Specialist Pulmonary & Sleep Disorders of NJ Plainsboro, NJ
Assistant Medical Director Johns Hopkins Center for Sleep and Wellness Baltimore, MD
This event is being held during the 2022 American Academy of Neurology Annual Meeting at the following dates and locations:
Saturday, April 2, 2022
Monday, April 4, 2022
7:00 PM - 10:00 PM
7:00 PM - 10:00 PM
Sheraton Grand Seattle Grand Ballroom CD
Grand Hyatt Seattle Leonesa Ballroom I
Please note, this event is not a CME program nor will CME credits be given for attendance. This event is not a part of the official AAN Annual Meeting programming. © 2022 Idorsia Pharmaceuticals, Ltd. US-IDS-00322 2/22
Today’s Opening Luncheon Kicks off Four Days of Exhibit Hall Happenings continued from the cover Open daily from 11:30 a.m. to 4:00 p.m. through Wednesday, the Exhibit Hall promises to be the reunion you’ve been waiting for with countless opportunities to explore, discover, and connect through interactive exhibits, events, and experiences. Learn about the latest advancements in patient care, find products that add efficiencies to your practice, and gather resources that assist patients and caregivers. Building a trip to the Exhibit Hall into your Annual Meeting schedule is the only way to get new information from the diverse, neurology-focused companies that are here to help you and your patients. Additionally, the Exhibit Hall gives you the opportunity to:
Relax and recharge your devices—and yourself—while
connecting to colleagues at the Exhibit Hall Charging Lounges. With a variety of seating options and locations, you will surely find the spot that meets your needs. Even those on the go can charge their devices in the safety of the charging lockers.
Enjoy food, music, and fun at the Monday evening
Networking Reception from 4:00 p.m.–6:00 p.m. Sponsored by the AAN family of publications, Neurology ®, Neurology ® Clinical Practice, Neurology ® Neuroimmunology & Neuroinflammation, Neurology ® Genetics, Continuum®, Neurology Today ®, and Brain & Life® with Wolters Kluwer Health, AAN publishing partner.
Have a cup of coffee or specialty hot and iced espresso drink
at the Buzz Cafes. Whether you prefer regular or decaf, vegan, or half-and-half—they have the beverage for you!
Remember to Complete Your ‘Passport’ to Win Prizes!
650
647
646
645
644 642
140
239
242 339 340
342
440
442
640
538
638
755
855
753
853
751
851
749
849 847
745
845 843
741
841
139 137 135
134
235 233
132 231
131
126
234 333
332
434
Buzz Cafe
835
634
Career Fair Neighborhood
651
Don’t forget to complete your Exhibit Hall Passport for a chance to win prizes, including a grand prize drawing of a 2023 Annual Meeting registration and a three-night stay in an AAN preferred hotel—compliments of the Academy. Collect stickers from each company participating in that day’s passport and turn your passport into the ticket tumbler at that day’s premier sponsor for your chance to win prizes. With a new passport each day, you have new chances to win daily. Passports are available near Registration, at Meeting Information, and in the Exhibit Hall. Get today’s passport to see the full list of prizes and complete contest rules. Check out the Exhibitor Lineup!
833 831
232 331
228 230
328
528
426
Food Distribution
827
127
317
118
119
308
106
206
100
200
408
510
300
610
806
107
600
400
801 Exhibit Hall Walking Path
101
1715
1711 1709 1707
2022 Annual Meeting • AANextra
1705 1703 1701
1814
1710
Association Neighborhood
1713
4
1124 1223
1224
918
1018
1118
1218
4F
1708 1805 1706 1704 1700
1803 1801
4D
Association Neighborhood
110 111
103
1024
4E
115
109
924 1023
817
617
418
First Time Exhibitors
123
1226 1327 1326
1812 1810 1808 1806 1804 1800
908
900
1008
1000
Charging Furniture Location 1208
1100
1200
Buzz Cafe
Booth Exhibitor
Booth Exhibitor
Booth Exhibitor
308
AbbVie
510
Eisai-Biogen
924
NeuroPace
400
AbbVie
109
Electrode Store
617
Novartis Pharmaceuticals
1208
AbbVie
132
Elsevier
827
Ochsner Health
426
AbbVie Medical
806
EMD Serono
644
Octapharma
328
Acadia Pharmaceuticals Inc.
749
European Academy of Neurology
1803
Octave
442
Acadia Pharmaceuticals Inc.
801
Genentech
119
Optum Infusion Pharmacy
107
Acorda Therapeutics
134
Global Kinetics
1810
Parkinson's Foundation
1226
Acorda Therapeutics
1326
Great Lakes NeuroTechnologies Inc.
137
Pfizer
110
Alexion
646
Helximith USA
231
Philips
100
Alnylam Pharmaceuticals
126
Horizon Therapeutics
228
Piramal Critical Care
1715
Alzheimer's Association
1805
Idorsia Pharmaceuticals
831
Provider Solutions & Development
1703
American Board of Psychiatry and Neurology, Inc. (ABPN)
1708
Idorsia Pharmaceuticals- Medical
232
PTC Therapeutics
123
AmerisourceBergen
651
Immunovant
1018
Quest Advanced Neurology
408
Amgen, Inc
106
Impel NeuroPharma
849
RosmanSearch
1200
Amneal Specialty, a division of Amneal Pharmaceuticals LLC
833
Indiana University Health
853
235
Insightec
Saint Luke’s Marion Bloch Neuroscience Institute
1704
Amprion
1223
Interacoustics
600
Sanofi
342
Amylyx
1711
Sarepta Therapeutics
139
ANI Pharmaceuticals, Inc.
International Essential Tremor Foundation
434 900
SK Life Science
317
argenx
1804
International Parkinson and Movement Disorder Society (MDS)
835
Spectrum Health
1801
Atara Bio
233
JAMA Network
755
Supernus - Medical Affairs
650
Avion Pharmaceuticals
331
Janssen Pharmaceuticals, Inc.
1100
Supernus Pharmaceuticals
242
Axiva Health Solutions, Inc
855
234
Takeda
753
Axsome Therapeutics
Kaiser Permanente / Permanente Medical Groups
418
Teva Pharmaceuticals
649
Billings Clinic - Health System
647
Kyowa Kirin
118
TG Therapeutics
817
Biogen
440
Labcorp
1705
The American Institute of Balance
332
Biohaven Pharmaceuticals
528
Lilly Alzheimer's
1814
The National ALS Registry
640
BioSerenity, Inc
206
LivaNova Epilepsy
642
Theranica USA
135
Boston Scientific
140
LocumTenens.com
340
TrueLearn
1124
BrainCheck
918
Lundbeck
1000
UCB, Inc.
1008
Bristol Myers Squibb
1710
Medpro
1808
610
Cadwell Laboratories, Inc.
239
Medscape Neurology
United Council for Neurologic Subspecialties Upsher-Smith Laboratories, Inc.
Cala Health, Inc.
Medtronic, Inc.
333
339
1118
Canvas Dx by Cognoa
Merck
Verana Health
1700
1023
1701
Merz Therapeutics
Viatris
Catalyst Pharmaceuticals, Inc
634
103
111
Ceribell
Merz Therapeutics
Vidant Health
745
741
841
Mitsubishi Tanabe Pharma America
Vituity
CND Life Sciences
1224
845
127
CNS Vital Signs
Mitsubishi Tanabe Pharma America
Weatherby Healthcare
638
1327
847
MotherToBaby Pregnancy Studies
Wolters Kluwer
Consolidated Neuro Supply
1806
908
101
Corinthian Reference Lab
MultiCare Health System
World Federation of Neurology
131
843
751
National Ataxia Foundation
Xenon Pharmaceuticals
Covenant HealthCare
1713
1800
851
Cyclic Vomiting Syndrome Association
National Institute of Neurological Disorders and Stroke (NINDS)
Xoran Technologies, LLC.
1707
1812
115 200
Zeto
538
Zogenix, Inc.
1709
Defeat MSA Alliance & MSA United Consortium
230
Neurelis, Inc
1024
Neurocode USA
645
Edward Hospital and Health Services
300
Neurocrine Biosciences
1706
Neurologist Connect, A Skipta Community
1218
Eisai Inc.
2022 Annual Meeting • AANextra
5
2021 Successes Touted at AAN Business Meeting The annual Business Meeting of the American Academy of Neurology was held yesterday, and the 2021 activities and finances were highlighted by President Orly Avitzur, MD, MBA, FAAN; CEO Mary E. Post, MBA, CAE; and Treasurer Charles C. Flippen II, MD, FAAN. After convening the meeting, Avitzur reviewed the Academy’s vision, mission, and core values. She cited the AAN as the world’s largest professional association of neurologists with 38,000+ members, including thousands of members who serve in 6,800 volunteer positions, as well as 200 staff. She spoke of progress on her presidential platform, the impact of COVID-19, global outreach efforts, and other major initiatives. Avitzur also highlighted newly established committees and subcommittees and their efforts: Academic Committee; IDEAS (Inclusion, Diversity, Equity, Antiracism, and Social Justice) Subcommittee; Committee on Public Engagement, which guided the development of the new Brain & Life podcast; Telehealth Subcommittee; and Wellness Subcommittee. Treasurer Flippen outlined financial results for 2021, with AAN consolidated operating revenues of $53 million and $46.4 million in expenses. From a financial standpoint, 2021 surpassed expectations amid the many uncertainties caused by the pandemic. Leading the way on the revenue side were royalties and publications with 44 percent of income, followed by membership dues, conferences and education, and grants and gifts. Education activities made up 24 percent of expenses, followed by administrative, advocacy, membership, grants and awards, and publications. In all, 79 cents of every dollar of revenue was used to support member products and services.
6
2022 Annual Meeting • AANextra
CEO Post called out the Academy’s continued record membership growth to more than 38,000 (including members in arrears). The AAN has 92 percent US market share of neurologists, based on 2020 data, and now has more than 1,900 advanced practice provider members as well as its highest membership for students (6,100+) and juniors (5,400+ residents and fellows). The CEO also spotlighted accomplishments in education, publications, advocacy, and other initiatives. To learn more about last year’s successes, read the AAN 2021 Annual Report at AAN.com/AnnualReport.
New Brain & Life Podcast Debuts
Daniel J. Correa, MD, FAAN
Audrey R. Nath, MD, PhD
The AAN’s new Brain & Life podcast is an entertaining weekly podcast exploring the intersection of brain health and neurologic disease. Join neurologist co-hosts Daniel J. Correa, MD, FAAN, and Audrey R. Nath, MD, PhD, in lively conversations with neurology experts, celebrity advocates, and people whose lives are affected by brain conditions. The podcast will educate and inspire people to maintain a healthy brain and a healthy you. “This is an exciting tool to amplify the community’s voice, support public health education, and reduce stigma for the one in six persons with neurologic conditions,”
A R E
Y O U
R E A D Y
said Correa. “For our colleagues, we hope the episodes are not just an enjoyable insight into patient perspectives, but also a resource to your patients and their families. We welcome your input on topics, guests, and medical experts to highlight in our schedule. Join us each week on your favorite podcast platform.” "It's so exciting to be able to reach out and bring stories of living with neurological conditions from real people,” Nath said. “We get to speak with patients and caregivers, both well known to the public as well as family members in the community. It is an honor to help our patients tell their stories and include up-to-date information from experts as well." New episodes of the Brain & Life podcast will come out weekly on Thursdays. Follow and subscribe wherever you get your podcasts! Scan to visit WEBPAGE
T O
C H A N G E
Y O U R
P E R S P E C T I V E ? In the management of MS, there’s still so much to discover. That is why here at Sanofi, we are committed to developing innovations that will change the way we look at MS.
Visit us at Booth 600 Not actual patients and HCPs. ©2022 Genzyme Corporation. All rights reserved. MAT-US-2200457-v1.0-02/2022
Today’s Invited Science Examines Epilepsy Today’s Invited Science Session from 1:00 p.m. to 3:00 p.m. on epilepsy will feature authors giving encore presentations of top abstracts presented at subspecialty meetings. The session is presented in partnership with the American Epilepsy Society. Select abstracts will emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of epilepsy with the overall goal of developing more effective prevention and treatment. Abstracts and authors include:
Traumatic Brain Injury Causes Cell Type-specific Remodeling of the Extracellular Matrix and Loss of the GABAergic Synaptogenic Factor Collagen 19a1 Sadi Quinones, Boston, MA 1:00 p.m.–1:20 p.m.
Common Risk Variants for Epilepsy Are Enriched in Families Previously Targeted for Rare “Monogenic” Variant Discovery
Genetic Diagnosis in Pediatric Epilepsy Impacts Medical Management Isabel Haviland, MD, Boston, MA 2:00 p.m.–2:20 p.m.
Laser Interstitial Thermal Therapy for Mesial Temporal Lobe Epilepsy: Multicenter Study in 268 Consecutively Treated Patients Including Outcomes of Subsequent Temporal Lobectomy for Seizure Recurrence Brett Youngerman, MD, MS, New York, NY 2:20 p.m.–2:40 p.m.
Brain Aging in Childhood-onset Epilepsy: A Prospective Population-based Study Bruce Hermann, PhD, Madison, WI 2:40 p.m.–3:00 p.m.
Colin A. Ellis, MD, Philadelphia, PA 1:20 p.m.–1:40 p.m.
An Expanded Genotype-phenotype Analysis of 11,500 People with Epilepsy David James Lewis-Smith, MD, Newcastle, United Kingdom 1:40 p.m.–2:00 p.m.
Medical Students Connect with the Pros for Valuable Insights Today’s Medical Student Symposium: Careers in Neurology, to be held from 12:00 p.m.–5:30 p.m. in the Washington State Convention Center, Room 6E, is specifically designed for medical students to explore the exciting career opportunities within neurology and network with other students. Students will gain an understanding about careers in neurology, the various subspecialty areas in neurology, and be able to network with residents and neurologists. Starting with an hour-long luncheon at noon, the event features an address by keynote speaker Saima Kayani, MD, followed by some interaction time between physicians and residents meeting with the medical students. Two Innovation Talks will then cover gene therapy and technological advances. From 4:00 p.m.–5:00 p.m., students will meet and speak with physicians who represent various neurology subspecialties and who will share information about their subspecialty, their education and career paths, how they maintain a work-life balance, etc.
8
2022 Annual Meeting • AANextra
SPECIALTY NETWORKING Behavioral Neurology and Neuropsychiatry
Neuroendovascular Surgery
Child Neurology
Neuroinfectious Disease
Epilepsy
Neuro-immunology
General Neurology
Neuromuscular
Global Neurology
Neuro-oncologist
Headache/Sports
Neuropalliative Care
Integrated Health & Wellness
Sleep
Movement Disorders
Sports Medicine/Neurology
Multiple Sclerosis
Traumatic Brain Injury/Sports
Neurocritical Care
Vascular/Stroke
Applications Open for Three Transformative Leadership Development Opportunities Applications are now open for three premier AAN Leadership Development Programs: Diversity Leadership, Emerging Leaders, and Practice Leadership. These unparalleled development opportunities arm participants with the foundational tools necessary to achieve their desired leadership potential and success within their careers, the Academy, and patient care. Visit AAN.com/lead for more information and eligibility requirements, and to apply or recommend a deserving colleague for one of these transformative programs. Interested applicants are also encouraged to stop by the Leadership University Learner Engagement Center to learn more and talk to program graduates about their experiences!
AAN LEADERSHIP DEVELOPMENT
Roy H. Hamilton, MD, MS, FAAN Diversity Leadership Program 2017 Graduate
FORGE YOUR PATHWAY IN NEUROLOGY DIVERSITY LEADERSHIP PROGRAM
EMERGING LEADERS PROGRAM
PRACTICE LEADERSHIP PROGRAM 2022 Annual Meeting • AANextra
9
Get Ready to Reunite at Tonight’s Great Neuro Reunion Party! It’s been a long two years—but tonight is your chance to finally reunite with your friends and colleagues when we all come together for the Great Neuro Reunion from 7:00 p.m. to 10:00 p.m.! Get ready for a long-awaited evening filled with world-class art, architecture, and culture with the chance to visit two of the most iconic Seattle destinations—all while sampling amazing local dishes and delicious beverages and enjoying live music. With the two attractions located within a block of one another, it will be the ultimate block party! Attendees will enjoy spectacular entertainment options, including:
Museum of Pop Culture (MoPOP)
Chihuly Garden and Glass Bringing together all the elements of famous artist Dale Chihuly’s work—including drawings, his signature glass series, large architectural installations, and personal collections—this visually stunning exhibition features eight galleries, the Garden with beautiful monumental sculptures, and the centerpiece Glasshouse.
Designed by internationally acclaimed architect Frank O. Gehry, MoPOP’s colorful and sprawling exterior hints at the unusual surprises that await inside.
Pre-reserved tickets will be distributed with your conference badge at Registration. You and your guest (if applicable) must show your vaccine verification wristband and Great Neuro Reunion party ticket to be admitted. Tickets that are not picked up by 5:00 p.m. today will be released. If you didn’t register for the Great Neuro Reunion, be sure to stop by Registration between 5:30 and 6:30 p.m. today to see if there are any extra tickets available. Tickets include all-you-caneat food, two drink tickets, entertainment, and transportation to and from hotels. Shuttles will be picking up at the Washington State Convention Center, the Fairmont Olympic Hotel, and the Hyatt Regency Seattle. Additional guest tickets may still be purchased for $115 at Registration. Any guests attending must also meet the vaccination requirements for the Annual Meeting and show proof of vaccination at the Registration area in Yakima Level 1 by 5:00 p.m. to attend the party. What part of the Great Reunion Party are you most excited about? Join the conversation at #AANAM and tag @AANmember!
10
2022 Annual Meeting • AANextra
What Are Your Colleagues Saying?
Share your thoughts at #AANAM. Join the conversation!
#AANAM
Elisabeth Van de Craen, MD, and Helena Gossye University of Antwerp, Belgium International Scholarship recipients What brings you to the Annual Meeting? We were speakers at the 2020 AAN Annual Meeting. We were supposed to speak in Toronto but then spoke at the virtual meeting. Now we are speaking this year at a scientific session about dementia. It’s more exciting to be here and get to see the people you’re speaking to. And you get better questioning. What else are you looking forward to? We are working on our PhDs now, but next year we will be starting in hospital, so we need to pick up information on other clinical fields. And of course networking with people in our field.
Luis J. Forastieri, MD Solo practitioner neurologist, Caguas, Puerto Rico What did you miss about the AAN Annual Meeting during the pandemic? Interacting with neurologists to get objective information about new drugs and new treatments, not just relying on drug reps. What draws you to the AAN Annual Meeting? It’s one of the best conferences in the whole country, really in the whole world. You can really get information on many conditions all in one meeting. I practice general neurology, so I need to cover many areas.
Khadija Awais, MBBS Resident, University of Tennessee, Memphis First-time attendee, presenting poster with mini case series on cavernous malformations What do you think of the Annual Meeting so far? I love it. Everyone has been really kind and welcoming. I’m overwhelmed by how much amazing opportunity there is and everything going on here. Everything you could think of in neurology. I even saw a session on neurology and poetry. You have the creative and the intellectual.
MerryJean Losso, MD Resident, Vanderbilt University, Nashville, Tennessee First-time attendee, presenting poster on nervus intermedius neuralgia What are you looking forward to at the AAN Annual Meeting? The Great Neuro Reunion. Meeting my colleagues I’ve seen on Zoom for the last two years. Seeing the advances in my subspecialty.
2022 Annual Meeting • AANextra
11
TODAY'S FEATURED BOOTH
Continuum: Lifelong Learning in Neurology® Visit the Continuum® booth in the Atrium Lobby to receive a discount on subscriptions, purchase back issues, and pick up giveaway items. This once-a-year savings for AAN members and nonmembers offers 15-percent off subscriptions and renewals. AAN members pay just $339 per year for both Continuum and Continuum® Audio and can lock in that rate for up to three years! The booth is open 7:00 a.m. to 6:00 p.m. on Saturday and 7:00 a.m. to 5:30 p.m. Sunday through Thursday. If you’re unable to make it to the booth you can still receive the discount by ordering online at continpub.com/AM2022. Don’t miss these topics!
2022 February: Neurology of Pregnancy April: Epilepsy June: Dementia August: Multiple Sclerosis and
Other CNS Inflammatory Diseases October: Movement Disorders December: Muscle
and Neuromuscular Junction Disorders
2023 (order subject to change) February: Neuroimaging April: Cerebrovascular Disease June: Neurology of
Systemic Disease August: Sleep Neurology October: Peripheral Nerve and
Motor Neuron Disorders December: Neuro-oncology
12
2022 Annual Meeting • AANextra
Today’s Implementation Science Course Taking Place in Learner Engagement Center Make your way to the Research Connections area within the Learner Engagement Center in Hall 4C-4 of the Washington State Convention Center today from 1:30 p.m. to 4:30 p.m. as Clinical Research Subcommittee Chair H E Hinson, MD, MCR, FAAN, welcomes experts on an exciting new topic—Implementation Science: How to Translate Policy Into Real-world Change. Implementation science is the study of practice change in the "realworld," including developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. Implementation can be used to study nearly any topic, but a special focus of this program will be on addressing health care disparities. H E Hinson, MD, MCR, FAAN
The half-day course is aimed at junior investigators, as well as experienced investigators who are looking to adopt new methods. Topics and presenters will include: Course Welcome / Opening Thoughts
Clinton B. Wright, MD, FAAN
Introduction to Implementation Science
Christian D. Helfrich, MPH, PhD
Coordinated Care Models and Implementation
Barbara G. Vickrey, MD, MPH, FAAN
Care Ecosystem in a Series of Diverse, Community-based Settings
Elan Guterman, MD
Identifying and Engaging Community Stakeholders
Lesli Skolarus, MD
Novel Methods for Studying Implementation Interventions
Janet Bettger, ScD, FAHA
Capturing and Coding Qualitative Data
Raina Croff, PhD
The Research Connections area is just one of five new Learner Engagement Centers debuting at this Annual Meeting. These dedicated spaces are designed to foster collaborative learning, offer unique education delivery methods, and spark engaging conversations.
The Role of Industry at the AAN Annual Meeting As we come back together for the Great Neuro Reunion to focus on the latest in neurology and improved patient care, there are three primary reasons the meeting would not be a complete reunion without the presence of industry.
AAN and Industry Share a Common Mission Industry shares and supports the AAN’s mission to promote the highest quality patient-centered neurologic care. The AAN and industry may pursue this mission in different ways—and there may sometimes be conflicting interests—but there is much to learn from each other, especially as both entities work toward common goals. Industry has and shares resources that can add value to attendees’ Annual Meeting experience and to their roles treating patients with neurologic conditions.
Dialogue Is Important
At the Annual Meeting, industry is looking for what they can do to support the needs of neurology and individual health care providers, which is often what attendees are seeking to improve their patients’ care. Dialogue leads to understanding, and there are multiple options at the Annual Meeting to start the conversation. Attendees are encouraged to visit the Exhibit Hall booths, ask specific questions, and take part in networking in and outside the Exhibit Hall.
Industry Has Valuable Information to Share Education and sharing of resources are at the core of industry’s participation at the meeting, according to a 2021 survey to the AAN’s Industry Roundtable, currently a group of 41 companies committed to a deeper understanding of and engagement with the AAN. As important as the Exhibit Hall is for finding hundreds of professional resources, attendees can also gain knowledge about research, technologies, and promising pipelines through industry presentations, career exploration, and Industry Therapeutic Updates.
8.25"
Learn how to put the power of
TREATING & PREVENTING to work for your patients1
Visit BOOTH 332 See the science Hear the speakers Request samples
Not actual tablet size.
Reference: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc.
© 2022 Biohaven Pharmaceuticals, Inc. NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC. Biohaven is a trademark of Biohaven Pharmaceutical Holding Company Ltd. US-RIMODT-2200120 02/24/2022
Today’s Experiential Learning Area Highlights Look for two Experiential Learning Areas for an interactive way of learning that will engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally. Here are today’s highlights:
HeadTalks
The Neurology of Wine Tasting
Atrium Lobby
4:00 p.m.–4:45 p.m.
Jaime R. Lopez, MD, will lead the group in discussing wine from a neurologic perspective. This discussion will top off with a complimentary wine tasting hosted by sommelier Youbirt Aissa.
Neuro-Jeopardy: Telencephalon Twisters 12:00 p.m.–12:45 p.m.
Jaime R. Lopez, MD
Veronica E. Santini, MD, MA
Okeanis Vaou, MD, FAAN
Test your neurologic fortitude against top neurologists, or simply sit back and watch the action directed by hosts Veronica E. Santini, MD, MA, and Okeanis Vaou, MD, FAAN.
The Best Things Happen While You’re Dancing: A Look at the Neurotherapeutic Power of Dance in Parkinson’s Disease 1:00 p.m.–1:45 p.m.
Live Well
Skybridge Lobby
Magic and Medicine 5:00 p.m.–5:30 p.m.
California Northstate University medical student Alan Chien will introduce participants to the art of magic, explore magic's intrinsic connection to neurology, and uncover evidence-based applications integrating the performance of magic within medicine.
Join us for an interactive demonstration of dance therapy with patients and instructors from the Seattle Theatre Group Dance for PD Class. Experience the power of music and dance, and why the best things happen while you’re dancing!
Joyce K. Lee-Iannotti, MD, and Muhib Khan, MD, led the action as the Neuro Feud teams battled it out to see who could best guess their fellow neurology professionals’ answers to survey questions.
14
2022 Annual Meeting • AANextra
LEC
Today’s Learner Engagement Center Highlights Academic Exchange
Leadership University
Ask Me Anything: Three Chairs, Three Opinions
Team Building in Medicine: How to Incorporate Your Strengths in Medical Teams
Tahoma 1
Hall 4C-1 and 4C-2
1:00 p.m.–1:45 p.m.
Bring your challenging scenarios, biggest barriers, and curiosity to this lively session with three neurology chairs: Merit E. Cudkowicz, MD, MSc, Laurie Gutmann, MD, FAAN, and Kathleen M. Shannon, MD, FAAN.
1:00 p.m.–1:30 p.m.
Wendell Bobb, MD, will present on how to use one's personal and professional strengths to make a stronger medical team.
Wendell Bobb, MD
Leveraging Inclusion to Mitigate Bias in Times of Crises Merit E. Cudkowicz, MD, MSc
Laurie Gutmann, MD, FAAN
Kathleen M. Shannon, MD, FAAN
Dollars and Sense: Faculty Compensation Models in Academic Neurology 2:00 p.m.–2:45 p.m.
Thabele M. Leslie-Mazwi, MD; Sheila Phicil, MPH, MS, PMP; and Jana Pettit, MBA, will review several current models for neurology academic faculty compensation and relation to funds flow. Business administrators will participate in Q&A in panel format. Attendees will gain an appreciation of how neurologists are currently compensated and the pluses and minuses of these models, incentive structures, current flashpoints such as pay equity, and how compensation may evolve in the future. Bring your questions!
Practice and Policy Engagement Center Hall 4C-3
Telehealth Panel: Ask Us Anything 2:35 p.m.–3:35 p.m.
Curious about teleneurology? Join a panel of telehealth experts to ask all of your questions about running a telehealth operation.
3:00 p.m.–4:30 p.m.
During this interactive program, participants will learn more about the concept of bias and how it impacts the practice of neurologic care, development of a representative and inclusive workforce, and outcomes of the care delivered.
Research Connections Hall 4C-4
Implementation Science: How to Translate Policy into Realworld Change 1:30 p.m.–4:30 p.m.
Learn about the foundations of implementation science, including how to translate policy into real-world change. Faculty will provide an overview of what implementation science is, the use of implementation models and frameworks, mixed methods, and community engagement in research, especially in vulnerable communities.
Neuro Trainee and Educator Junction Tahoma 3 and Tahoma 4
An Introduction to Neurology Subspecialties: Stroke & Vascular Neurology; Critical Care & Emergency Neurology; Neuro-oncology; Neuro-ophthalmology/Neuro-otology 4:30 p.m.–5:30 p.m.
Trainees will obtain information on various neurology subspecialties to help them navigate their career paths.
2022 Annual Meeting • AANextra
15
Congratulate These AAN Service Awards Recipients Take a moment to offer your congratulations to these neurology professionals who are being honored for their service during the Annual Meeting. Visit the Awards Theater to learn more or find the complete list of 2022 AAN award recipients at AAN.com/research/ award-recipients.
AAN PRESIDENT'S AWARD David A. Evans, MBA Texas Neurology, Dallas, TX
Sunday, April 3, 9:15 a.m.–12:00 p.m. Presidential Plenary Session
AMBASSADOR AWARD Sponsored by the American Brain Foundation.
Susannah Cahalan Wednesday, April 6, 6:00 p.m. Commitment to Cures Gala, Hyatt Regency Ballroom
AWARD FOR CREATIVE EXPRESSION OF HUMAN VALUES IN NEUROLOGY Sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society.
James Dolbow, DO University Hospitals Cleveland Medical Center, Cleveland, OH
KENNETH M. VISTE JR., MD PATIENT ADVOCATE OF THE YEAR AWARD Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends, and patients.
Nirmal Surya, MD, DNB, FIAN, FRCP Epilepsy Foundation India, Mumbai, India
MRIDHA SPIRIT OF NEUROLOGY HUMANITARIAN AWARD Sponsored by the American Brain Foundation and funded through the philanthropy of Dr. and Mrs. Mridha.
Bindu Menon, MD, DM, DNB, PGDCN, FRCP, MNAMS, FICP, FIAN, FWSO Apollo Specialty Hospitals, Andhra Pradesh, India
Bruce Ovbiagele, MD, MSc, MAS, MBA, FAAN University of California, San Francisco, CA
NEUROLOGY® RESIDENT & FELLOW SECTION WRITING AWARD Sponsored by Neurology Resident & Fellow Section.
A. Chris Espinoza, MD University of Utah, Primary Children’s Hospital, Salt Lake City, UT Melissa A. Wright, MD University of Utah, Primary Children’s Hospital, Salt Lake City, UT
Meghan S. Candee, MD, MS University of Utah, Primary Children’s Hospital, Salt Lake City, UT
Cristina Trandafir, MD, PhD Texas Children's Hospital, Baylor College of Medicine, Houston, TX Gary R. Nelson, MD University of Utah, Primary Children’s Hospital, Salt Lake City, UT
For their article: “Child Neurology: Lateonset Vitamin B6–Dependent Epilepsy Identified by Rapid Genome Sequencing”
16
2022 Annual Meeting • AANextra
QI INNOVATION AWARD Sponsored by the American Academy of Neurology.
Lindsey A. Morgan, MD Seattle Children's Hospital, Seattle, WA Michael P. Skolka, MD Mayo Clinic, Rochester, MN
TED BURNS HUMANISM IN NEUROLOGY AWARD Sponsored by the American Brain Foundation.
Barbara S. Giesser, MD, FAAN Pacific Neuroscience Institute, Santa Monica, CA
PUBLIC LEADERSHIP IN NEUROLOGY AWARD Sponsored by the American Brain Foundation.
Seth Rogen and Lauren Miller Rogen Wednesday, April 6, 6:00 p.m. Commitment to Cures Gala, Hyatt Regency Ballroom
GENERAL NEUROLOGY AWARD Sponsored by the American Academy of Neurology.
Sally Harris, MD, FAAN Sandia Neurology PC, Albuquerque, NM Monday, April 4, 11:30 a.m.–11:45 a.m. Awards Theater
Artificial Intelligence Is Focus of Today’s Neuroscience in the Clinic Session
Antonio M. P. Omuro, MD
Sunil Sheth, MD
Sanjay Aneja, MD
Today, between 3:30 p.m. and 5:30 p.m., join expert faculty Antonio M. P. Omuro, MD; Sunil Sheth, MD; and Sanjay Aneja, MD, for Neuroscience in the Clinic: Applications of Artificial Intelligence and Machine Learning Tools in Neurology. Ashby Turner, MD; Yujin Kim; Mariam Aboian, MD, PhD; and Benjamin Henry Brinkman, PhD, will each present abstracts related to this topic during the session. The presenters will showcase abstracts and discuss recent applications of artificial intelligence (AI) within the field of neurology and highlight recent successes as well as existing challenges in AI applications in clinical practice for a variety of specialties, including stroke, neuro-oncology, epilepsy, multiple sclerosis, neuroimaging, and more. Machine learning scientists will review the underlying principles, discuss the latest technological advances in the field, and provide tools to help attendees understand the literature and embrace novel technologies. The session will conclude with a panel discussion along with opportunity for questions. Attendees may claim two CME credits.
Make a difference at Cedars-Sinai! Cedars-Sinai is one of the largest and fastest growing nonprofit academic medical centers in the U.S. and we are proud to be recognized as one of the top hospitals in Neurology and Neurosurgery in the nation. Alongside the Biomedical Imaging and Research Institute, Regenerative Medicine Institute, Department of Neurosurgery, and the Center for Neural Sciences, we also have an abundance of collaborative resources, programs, and benefits available at Cedars-Sinai.
Available Positions:
• Director, Jona Goldrich Center for Alzheimer’s & Memory Disorders • Director, Neuromuscular • Neurohospitalist and Stroke • NeuroICU • Behavioral/Cognitive neurology For more information please contact Academic Recruiting at Academic.Recruiting@cshs.org
THE EARLY LEVODOPA/CARBIDOPA PARTNER FOR OFF TIME THAT ENHANCES LEVODOPA1,2
Increased levodopa exposure by up to 74%,
Started to reduce off time as early as 1 week*
No titration required— one capsule, taken at bedtime1
helping more levodopa be available to reach the brain1,2
with significant reductions of 2 hours vs. 1 hour with placebo seen at 14/15 weeks†—studied through 1 year1,2
• Patients should not eat food for 1 hour before and at least 1 hour after taking ONGENTYS1
ONGENTYS was generally well tolerated in clinical studies.1 *At Week 1: -1.24 hours vs -0.42 hours for placebo in Study 1; -1.22 hours vs -0.47 hours for placebo in Study 2.2 † For Study 1: -1.95 hours vs -0.93 hours with placebo (P=0.002) at Week 14/15; adjusted P value was calculated using a gatekeeping procedure controlling for multiplicity For Study 2: -1.98 hours vs -1.07 hours with placebo (P=0.008) at Week 14/15; adjusted P value was calculated using Dunnett’s alpha level adjustment to control for multiplicity.1
SEE THE FULL STORY AT ONGENTYSHCP.COM INDICATION & USAGE ONGENTYS® (opicapone) capsules is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ONGENTYS is contraindicated in patients with: • Concomitant use of non-selective monoamine oxidase (MAO) inhibitors. • Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms. WARNINGS & PRECAUTIONS Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-O-Methyltransferase (COMT) Possible arrhythmias, increased heart rate, and excessive changes in blood pressure may occur with concomitant use of ONGENTYS and drugs metabolized by COMT, regardless of the route of administration (including inhalation). Monitor patients treated concomitantly with ONGENTYS and drugs metabolized by COMT. Falling Asleep During Activities of Daily Living and Somnolence Patients treated with dopaminergic medications and medications that increase levodopa exposure, including ONGENTYS, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. If a patient develops daytime sleepiness or somnolence, consider discontinuing ONGENTYS or adjusting other dopaminergic or sedating medications and advise patients to avoid driving and other potentially dangerous activities. Please see additional Important Safety Information on back of page.
Pharmacokinetic Study Design: A randomized, open-label, Phase 1 study to assess the pharmacokinetics and pharmacodynamics of repeated doses of ONGENTYS 50 mg administered orally as adjunctive therapy to stable regimen of levodopa/carbidopa in patients with PD (N=16). Patients were randomized to receive immediate-release levodopa/ carbidopa, either every 3 hours (n=7) or every 4 hours (n=9). The data for this every-4-hour, or Q4H, population are shown above. All patients received once-daily ONGENTYS 50 mg in the evening from Days 1 to 14.2 Pivotal Studies Design: ONGENTYS was studied in two 14- to 15-week, double-blind, randomized, parallel-group studies of patients with PD experiencing off episodes being treated with levodopa/DDCI (alone or in combination with other PD medications). The double-blind period for each study began with an up to 3-week levodopa/DDCI adjustment period, followed by a stable maintenance period of 12 weeks. The primary endpoint of both studies was mean change in off time, based on 24-hour patient diaries completed 3 days prior to each of the scheduled visits. After the double-blind period, patients were able to enroll in a 1-year open-label extension of ONGENTYS. Patients who had been on placebo or active comparator in the double-blind period received ONGENTYS in the open-label period. For the majority of the extension period, investigators were able to adjust patients’ levodopa/DDCI according to clinical response.1,2
IMPORTANT SAFETY INFORMATION (CONT'D) WARNINGS & PRECAUTIONS
Hypotension/Syncope Monitor patients for hypotension and advise patients about the risk for syncope. If these adverse reactions occur, consider discontinuing ONGENTYS or adjusting the dosage of other medications that can lower blood pressure. Dyskinesia ONGENTYS potentiates the effects of levodopa which may result in dyskinesia or exacerbate pre-existing dyskinesia. Reducing the patient’s levodopa dosage or the dosage of another dopaminergic drug may reduce dyskinesia that occurs during treatment with ONGENTYS. Hallucinations and Psychosis Consider stopping ONGENTYS if hallucinations or psychotic-like behaviors occur. Patients with a major psychotic disorder should ordinarily not be treated with ONGENTYS. Impulse Control/Compulsive Disorders Patients may experience intense urges (eg, gambling, sexual, spending money, binge eating) and the inability to control them. It is important for prescribers to specifically ask patients or their caregivers about the development of new or increased urges. Re-evaluate the patient’s current therapies for Parkinson’s disease and consider stopping ONGENTYS if a patient develops such urges while taking ONGENTYS. Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (elevated temperature, muscular rigidity, altered consciousness, and autonomic instability) has been reported in association with rapid dose reduction or withdrawal of drugs that increase central dopaminergic tone. There were no reports of neuroleptic malignant syndrome in ONGENTYS controlled clinical studies. When discontinuing ONGENTYS, monitor patients and consider adjustment of other dopaminergic therapies as needed. ADVERSE REACTIONS
The most common adverse reactions (incidence at least 4% and greater than placebo) were dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, and weight decreased. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Please see adjacent page for brief summary of PI and visit ONGENTYShcp.com/pi for full PI. References: 1. ONGENTYS [package insert]. San Diego, CA: Neurocrine Biosciences, Inc; 2020. 2. Data on file. Neurocrine Biosciences, Inc.
©2022 Neurocrine Biosciences, Inc. All Rights Reserved. CP-OPC-US-0615 04/2022 The information contained herein is intended for use by U.S. healthcare professionals only. Neurocrine Biosciences rights to promote, offer for sale, and sell ONGENTYS is limited to the U.S.
Under license from
ONGENTYS® (opicapone) capsules, for oral use
Dyskinesia
The following is a brief summary; for full Prescribing Information and Patient Information, refer to package insert.
ONGENTYS potentiates the effects of levodopa and may cause dyskinesia or exacerbate pre-existing dyskinesia.
INDICATIONS AND USAGE ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
CONTRAINDICATIONS ONGENTYS is contraindicated in patients with: • Concomitant use of non-selective monoamine oxidase (MAO) inhibitors. • Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
WARNINGS AND PRECAUTIONS Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-O-Methyltransferase (COMT) Possible arrhythmias, increased heart rate, and excessive changes in blood pressure may occur with concomitant use of ONGENTYS and drugs metabolized by COMT (e.g., isoproterenol, epinephrine, norepinephrine, dopamine, and dobutamine), regardless of the route of administration (including inhalation). Monitor patients treated concomitantly with ONGENTYS and drugs metabolized by COMT.
Falling Asleep During Activities of Daily Living and Somnolence Patients treated with dopaminergic medications and medications that increase levodopa exposure, including ONGENTYS, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event. Before initiating treatment with ONGENTYS, advise patients of the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with dopaminergic therapy, such as concomitant sedating medications or the presence of a sleep disorder. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), consider discontinuing ONGENTYS or adjusting other dopaminergic or sedating medications. If a decision is made to continue ONGENTYS, patients should be advised not to drive and to avoid other potentially dangerous activities.
Hypotension/Syncope In Study 1 and Study 2, hypotension (orthostatic and non-orthostatic), syncope, and presyncope occurred in 5% of patients treated with ONGENTYS 50 mg compared to 1% of patients who received placebo. Monitor patients for hypotension (orthostatic and non-orthostatic) and advise patients about the risk for syncope and presyncope. If these adverse reactions occur, consider discontinuing ONGENTYS or adjusting the dosage of other medications that can lower blood pressure.
In controlled clinical trials (Study 1 and Study 2), dyskinesia occurred in 20% of patients treated with ONGENTYS 50 mg compared to 6% of patients who received placebo. Dyskinesia was also the most common adverse reaction leading to discontinuation of ONGENTYS. Reducing the patient’s daily levodopa dosage or the dosage of another dopaminergic drug may mitigate dyskinesia that occurs during treatment with ONGENTYS.
Hallucinations and Psychosis In Study 1 and Study 2, hallucinations (hallucinations, auditory hallucinations, visual hallucinations, mixed hallucinations) occurred in 3% of patients treated with ONGENTYS 50 mg compared to 1% of patients who received placebo. Delusions, agitation, or aggressive behavior occurred in 1% of patients treated with ONGENTYS 50 mg, and in no patient who received placebo. Consider stopping ONGENTYS if hallucinations or psychotic-like behaviors occur. Patients with a major psychotic disorder should ordinarily not be treated with ONGENTYS because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone. In addition, treatments for psychosis that antagonize the effects of dopaminergic medications may exacerbate the symptoms of PD.
Impulse Control/Compulsive Disorders Patients treated with ONGENTYS can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more dopaminergic therapies that increase central dopaminergic tone. In some cases, these urges were reported to have stopped when the dose was reduced, or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending, or other urges while being treated with ONGENTYS. In Study 1 and Study 2, impulse control disorders occurred in 1% of patients treated with ONGENTYS 50 mg, and in no patient who received placebo. Re-evaluate the patient’s current therapy(ies) for Parkinson’s disease and consider stopping ONGENTYS if a patient develops such urges while taking ONGENTYS. Use with caution in Parkinson’s patients with suspected or diagnosed dopamine dysregulation syndrome.
Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone. In the controlled clinical studies of ONGENTYS, patients discontinued ONGENTYS treatment without dose tapering or gradual withdrawal. There were no reports of neuroleptic malignant syndrome in ONGENTYS controlled clinical studies. When discontinuing ONGENTYS, monitor patients and consider adjustment of other dopaminergic therapies as needed.
ADVERSE REACTIONS
DRUG INTERACTIONS
The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling:
Non-Selective Monoamine Oxidase (MAO) Inhibitors
• Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-O-Methyltransferase (COMT) • Falling Asleep During Activities of Daily Living and Somnolence • Hypotension/Syncope • Dyskinesia • Hallucinations and Psychosis • Impulse Control/Compulsive Disorders • Withdrawal-Emergent Hyperpyrexia and Confusion
Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ONGENTYS was evaluated in 265 patients with Parkinson’s disease (PD) in two 14-15 week placebo- and active-controlled (Study 1) or placebo-controlled (Study 2) studies. All patients were taking a stable dose of levodopa and a DOPA decarboxylase inhibitor, alone or in combination with other PD medications. In Study 1 and Study 2, the mean age of patients was 63.6 years, 59% of patients were male, and 89% of patients were Caucasian. At baseline, the mean duration of PD was 7.6 years. Adverse Reactions Leading to Discontinuation of Treatment In Study 1 and Study 2, a total of 8% of ONGENTYS 50 mg-treated patients and 6% of patients who received placebo discontinued due to adverse events. The most common adverse reaction leading to discontinuation was dyskinesia, reported in 3% of ONGENTYS 50 mg-treated patients and 0.4% of patients who received placebo. Common Adverse Reactions Adverse reactions that occurred in the pooled studies at an incidence of at least 2% and greater than placebo are presented in Table 1. The most common adverse reactions (incidence at least 4% and greater than placebo) were dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, and weight decreased. Table 1: Adverse Reactions with an Incidence of at Least 2% in Patients Treated with ONGENTYS and Greater than on Placebo, in Pooled Study 1 and Study 2 Adverse Reactions
Nervous system disorders Dyskinesia Dizziness Gastrointestinal disorders Constipation Dry mouth Psychiatric disorders Hallucination1 Insomnia Investigations Blood creatine kinase increased Weight decreased Vascular disorders Hypotension/syncope 2 Hypertension 1
2
ONGENTYS 50 mg N=265 %
Placebo N=257 %
20 3
6 1
6 3
2 1
3 3
1 2
5 4
2 0
5 3
1 2
Includes hallucinations, hallucinations visual, hallucinations auditory, and hallucinations mixed Includes hypotension, orthostatic hypotension, syncope, and presyncope
Both ONGENTYS and non-selective MAO inhibitors (e.g., phenelzine, isocarboxazid, and tranylcypromine) inhibit catecholamine metabolism, leading to increased levels of catecholamines. Concomitant use may increase the risk of possible arrhythmias, increased heart rate, and excessive changes in blood pressure. Concomitant use of ONGENTYS with non-selective MAO inhibitors is contraindicated. Selective MAO-B inhibitors can be used concomitantly with ONGENTYS.
Effect of ONGENTYS on Other Drugs Drugs Metabolized by Catechol-O-Methyltransferase (COMT) Concomitant use of ONGENTYS with drugs metabolized by COMT may affect the pharmacokinetics of those drugs, which may increase the risk of possible arrhythmias, increased heart rate, and excessive changes in blood pressure. Drugs known to be metabolized by COMT should be administered with caution. Monitor for changes in heart rate, rhythm, and blood pressure in patients concomitantly treated with ONGENTYS and drugs metabolized by COMT.
OVERDOSAGE No specific antidotes for ONGENTYS are known. As a general measure, removal of ONGENTYS by gastric lavage and/or inactivation by administering activated charcoal should be considered. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an over-exposure occurs, call your poison control center at 1-800-222-1222 or www.poison.org. For further information on ONGENTYS, call 1-833-ONGENTYS (833-664-3689) or visit www.ongentys.com Distributed by: Neurocrine Biosciences, Inc., San Diego, CA 92130 Under license from BIAL-Portela & Ca, S.A. ONGENTYS is a registered trademark of BIAL-Portela & Ca, S.A. Rx Only CP-OPC-US-0111 09/2020
Things to Enjoy in Seattle
Top coffee picks (in no order): Caffe Vita, Lighthouse Roasters, Milstead & Co., Starbucks Reserve Roastery (if you want a classic Seattle experience), Pegasus Coffee.
I would go to the Pike Place Market to see the food and flower stalls. The Market is famous for the fish sellers who toss their wares.
–UW Pediatric Neurology
If I had a little more time, I would go to Chihuly Garden and Glass in the Seattle Center (location of the Annual Meeting’s Great Neuro Reunion Party Sunday night). Dale Chihuly is a native Washingtonian, and his blown glass works are shown worldwide. –Christina M. Marra, MD
The Olympic Sculpture Garden is a beautiful park to visit downtown with walking paths and lovely views of the water to enjoy along the way. Of the many dining options, I am especially fond of the Sea Creatures group of restaurants, but wherever you choose to go make sure to enjoy some seafood! –Thabele (Bay) Leslie-Mazwi, MD
22
2022 Annual Meeting • AANextra
AAN Conferences Mobile App Daily Tip The AAN Conferences mobile app makes finding your way to sessions easier than ever. Tap “Maps” on the main menu navigation. From there you can select your starting point and destination and use interactive maps to help navigate the convention center to get to your next session. Don’t have the app yet? Download the AAN Conferences mobile app in the App Store or Google Play.
Available for iPhone, iPad, or Android
SUPPORTING PATIENTS WITH LEMS IN EVERY WAY WE CAN
The right treatment and support go hand in hand
Catalyst Pharmaceuticals created Catalyst Pathways®, a free, personalized program designed to help you and your adult patients manage the unique challenges of Lambert-Eaton myasthenic syndrome (LEMS) through: One-on-one support and education
Financial support programs
A dedicated team of specialists to navigate insurance
Patient Mentor Program
Catalyst Pathways® is a registered trademark of Catalyst Pharmaceuticals, Inc. © 2022 Catalyst Pharmaceuticals, Inc. All Rights Reserved. Printed in USA. 22LEM0636b January 2022
Find out more about all the ways Catalyst Pharmaceuticals is working to help support you and your patients. To learn more, visit YourCatalystPathways.com.
What excited you today at #AANAM? Gwen W Zeigler @gwen_zeigler
Happy to be at #AANAM! Even happier that they have these available. Available right by registration. @AANMember #Neurotwitter
Join the conversation at #AANAM
Brian Stamm, MD @brainstamm First in-person conference since intern year. I’m like a kid in a candy store @AANMember @NMNeurons #AANAM #NeuroTwitter
MIGRAINE
You are invited to the Nurtec ODT Industry Therapeutic Update at the 2022 American Academy of Neurology (AAN) Annual Meeting
TREATMENT IN ITS CL ASS as of 8/6/2021*
Eric Eross, DO, will present an
Industry Therapeutic Update From Biohaven Nurtec ODT: The First and Only Medication for the Acute and Preventive Treatment of Migraine1,2 Monday, April 4, 2022 | 7:00 - 8:00 pm PT Renaissance Seattle Hotel Municipal Room You must be registered for the 2022 AAN Annual Meeting to attend this presentation.
While at the 2022 AAN Annual Meeting, visit Booth 332 This industry therapeutic update is not for CME credit. CME credits will not be given for attendance. This program is not endorsed by the 2022 AAN Annual Meeting and is not a part of the 2022 AAN Annual Meeting Education on Scientific Programs. This presentation is consistent with the PhRMA Code on Interactions with Healthcare Professionals. NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC. Biohaven is a trademark of Biohaven Pharmaceutical Holding Company Ltd. © 2022 Biohaven Pharmaceuticals, Inc. New Haven, CT 06510. US-RIMODT-2200055 02/09/2022
INDICATION Nurtec ODT is indicated in adults for the: • acute treatment of migraine with or without aura • preventive treatment of episodic migraine IMPORTANT SAFETY INFORMATION Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration. Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT. Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp. Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease. Please see accompanying full Prescribing Information for Nurtec ODT by aiming your device here *Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed, number one in new prescriptions, and more neurologists selected as brand of choice. References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. doi:10.1016/S0140-6736(20)32544-7
DAILY REMINDERS For easy access to meeting links, visit AAN.com/QuickLinks.
3
Safety and COVID-19 Protocols
Attendee Breakfast and Lunch
Social distancing is encouraged where possible. Attendees are encouraged to do what feels best for them. The AAN requests all attendees be respectful of the preferences indicated by their fellow attendees.
Attendee breakfasts are served from 6:45 a.m.–7:45 a.m. in Hall 4B, Skagit Lower Level, and Tahoma Level.
Green: High fives and handshakes are okay with frequent
hand washing.
Yellow: Elbows only. Still being cautious.
Red: No contact. Maintain distance where possible.
The AAN is striving to ensure the safety of attendees through greater cleaning and sanitation efforts throughout the center. The Washington State Convention Center has received a Global Biorisk Advisory Council star certification, which is the cleaning industry’s gold standard for outbreak prevention, response, and recovery accreditation. Encore, our designated audio-visual provider, is ensuring that microphones, laptops, ePoster screens, and other equipment are cleaned between sessions. All attendees, staff, and vendors must wear a mask when indoors. Masks are required except in the following limited circumstances: When you are actively eating or drinking When you are a faculty member presenting at a lecture
or panel Need a mask? Extras are available at the Information Booth on Level 4. If you are feeling unwell, PCR testing will be available through GoLab at the Fairmont Olympic Hotel Seattle.
Attendee lunches are served from 11:30 a.m.–1:00 p.m. in the Poster Hall 4B only.
Education Program Syllabi and Slides Available Online Education Program syllabi and slides are available online only at AAN.com/materials or through the AAN Conferences mobile app.
Submit Evaluations for Annual Meeting CME Complete your evaluations to get your CME credits by using the AAN Conferences mobile app or by visiting AAN.com/view/CME. CME requests may be made through May 14, 2022, unless you have upgraded your registration to extend your access with Annual Meeting On Demand. Transcripts will be emailed approximately six weeks after the meeting. AAN members can also access their transcript via NeuroTracker™ at AAN.com/view/NeuroTracker.
Want More Time to Review Programs? Extend your access to Annual Meeting programs by upgrading your registration to include Annual Meeting On Demand. Access will be available until March 1, 2023, for most recordings. Check the back of your badge to see if you have already purchased Gold or Platinum registration. If not, head to Registration on Yakima Level 1 to upgrade.
If you need a test for travel, a no-cost PCR testing option is available on Level 1 of the Convention Center from Tuesday, April 5 to Friday, April 8, 2022. Maps of testing sites near the Washington State Convention Center will be available at the Information Booth on Level 4.
22 Annual Meeting
2022 Annual Meeting • AANextra
25
Look for Programs Throughout the Week Offering Unique Learning, Engagement Formats This Annual Meeting offers some exciting new programs designed to engage participants in new and unique ways. A departure from the didactic lecture, these opportunities employ small group discussions, role playing, and other interactive approaches to learning while offering 2 CME credits per course. Find these program locations in the conferences mobile app.
Create Your Own Byte of Neurology Monday, 7:00 a.m.–9:00 a.m. Director: Roy E. Strowd III, MD, FAAN Attendees will be able to describe the evidence-based teaching behind microlearning, have constructed a script for their own multimedia microlearning module, and have participated in a friendly competition to see whose module will be selected for inclusion in an upcoming AAN NeuroBytes course.
Meeting the Moment: Mastering Difficult Conversations in Serious Neurologic Illness Tuesday, 7:00 a.m.–9:00 a.m. Director: Jessica Michelle Sedley Besbris, MD Participants will be able to implement the SPIKES framework for disclosing serious news; demonstrate communication strategies for responding to patient emotion; and analyze an observed simulated clinical interaction for key elements of successful and suboptimal communication strategies.
Writing and Reviewing Multiple Choice Exam Questions Wednesday, 3:30 p.m.–5:30 p.m. Director: Jeremy Moeller, MD, FAAN This course aims to identify and educate future contributors to assessment tools from the AAN and other sources. Attendees will learn to identify a good concept for testing, depending on the learner, purpose of the assessment and relevant assessment standards; describe best practices for multiple choice question (MCQ) item writing and recognize common pitfalls; recognize sources of bias in MCQ item development; and develop and evaluate new MCQ items.
Theater of Health Care Equity Tuesday, 3:30 p.m.–5:30 p.m. Director: Nimish A. Mohile, MD, FAAN This course addresses interaction between patients, providers, and staff, enabling providers to confront bias while cultivating empathy and practicing effective communication. Through interactive theater techniques, participants can consider difficult encounters through activities that engage all their senses. The playfulness of theater opens the door for participants to move beyond endless conversation to act out problematic scenarios and creatively explore solutions.
26
2022 Annual Meeting • AANextra
APPs, Make the Most of Your Annual Meeting Experience! All the AAN’s 1,900 advanced practice provider members are automatically included in the Consortium of Neurology APPs (CNAPP). Those attending the Annual Meeting are invited to two exclusive business and networking events.
CNAPP Meeting
APP Networking Reception
Monday from 1:00 p.m.–2:00 p.m.
Tuesday from 4:00 p.m.–5:00 p.m.
Sheraton Grand Seattle, Metropolitan Room A
Room 211, Convention Center
Join CNAPP officers and colleagues to discuss 2022 APP offerings at the Annual Meeting.
Meet and mingle with your APP colleagues.
Brought to you by CND Life Sciences®
THE POWER OF PROOF Finally, accurate pathological evidence of a synucleinopathy with a simple skin-based test A reliable way to help diagnose: • Parkinson’s disease
• Pure autonomic failure
• Dementia with Lewy bodies
• REM sleep behavior disorder
• Multiple system atrophy
Learn more at SynOneTest.com Visit us at Booth #127 *Based on internal QI/QA data and data presented by Gibbons et al at the 2020 AAN Meeting (for patients with a clinically established synucleinopathy excluding RBD).
>95% Sensitivity & Specificity*
Convenient In-office Procedure
This is Where they go depends on where you start
GARY Started OCREVUS, 2019 at age 32
PASTELL Started OCREVUS, 2018 at age 34
EXPLORE OCREVUS AT BOOTH 801 © 2022 Genentech USA, Inc. All rights reserved. M-US-00014945(v1.0) 03/22
